About   Help   FAQ
Mammalian Phenotype Ontology Annotations
Query Results - Summary
Symbol
Name
ID 		Ifng
interferon gamma
MGI:107656
202 phenotypes from 9 alleles in 29 genetic backgrounds
Export: Excel File
Allelic Composition
Genetic Background		 Annotated Term Reference
Ifngtm1.1(KOMP)Vlcg/Ifng+
C57BL/6N-Ifngtm1.1(KOMP)Vlcg/Ucd 		abnormal lung morphology J:211773
decreased prepulse inhibition J:211773
increased hematocrit J:211773
Ifngtm1.1(KOMP)Vlcg/Ifngtm1.1(KOMP)Vlcg
C57BL/6N-Ifngtm1.1(KOMP)Vlcg/MbpMmucd 		embryonic lethality prior to organogenesis J:211773
embryonic lethality prior to tooth bud stage J:211773
Ifngtm1.1(KOMP)Vlcg/Ifngtm1.1(KOMP)Vlcg
C57BL/6N-Ifngtm1.1(KOMP)Vlcg/Ucd 		preweaning lethality, complete penetrance J:211773
Ifngtm1.1Hayg/Ifngtm1.1Hayg
Not Specified 		abnormal B cell differentiation J:220784
abnormal bone marrow cell morphology/development J:220784
abnormal circulating cytokine level J:220784
abnormal cytokine level J:220784
abnormal erythropoiesis J:220784
abnormal hematopoietic stem cell morphology J:220784
abnormal lymph node morphology J:220784
abnormal proerythroblast morphology J:220784
abnormal T cell activation J:220784
anemia J:220784
decreased bone marrow cell number J:220784
decreased common myeloid progenitor cell number J:220784
decreased erythrocyte cell number J:220784
decreased erythroid progenitor cell number J:220784
decreased granulocyte monocyte progenitor cell number J:220784
decreased leukocyte cell number J:220784
decreased mature B cell number J:220784
decreased megakaryocyte cell number J:220784
decreased megakaryocyte-erythroid progenitor cell number J:220784
decreased myeloid cell number in bone marrow J:220784
decreased pre-B cell number J:220784
impaired hematopoiesis J:220784
increased erythroblast number J:220784
increased hematopoietic stem cell number J:220784
increased nucleated erythrocyte cell number J:220784
increased T cell number J:220784
pancytopenia J:220784
spleen atrophy J:220784
thrombocytopenia J:220784
thymus atrophy J:220784
Ifngtm1Lky/Ifngtm1Lky
involves: 129S4/SvJae * C57BL/6 		normal immune system phenotype J:189794
Ifngtm1Ts/Ifngtm1Ts
B6.129S7-Ifngtm1Ts 		abnormal B cell physiology J:112084
abnormal cytokine secretion J:18801, J:110826
abnormal immunoglobulin level J:18801
abnormal lymph node cell ratio J:112084
abnormal response to infection J:18801, J:110826
abnormal response to transplant J:42090
decreased IgG2a level J:18801
decreased IgG3 level J:18801
decreased tumor latency J:77491
increased CD8-positive, alpha-beta T cell number J:112048
increased IgE level J:18801
increased IgG1 level J:18801, J:112048
increased interleukin-2 secretion J:112048
increased interleukin-5 secretion J:112048
increased interleukin-10 secretion J:112048
increased lymphoma incidence J:77491
increased sarcoma incidence J:77491
increased susceptibility to Coronaviridae infection J:112048
increased susceptibility to Coronaviridae infection induced morbidity/mortality J:112048
increased susceptibility to parasitic infection J:18801
increased susceptibility to parasitic infection induced morbidity/mortality J:18801, J:110826
increased T cell derived lymphoma incidence J:77491
premature death J:77491
Ifngtm1Ts/Ifngtm1Ts
B6.129S7-Ifngtm1Ts/J 		abnormal circulating cytokine level J:47459
abnormal cytokine secretion J:120556
abnormal dendritic cell antigen presentation J:134949
abnormal dendritic cell chemotaxis J:134949
abnormal dendritic cell physiology J:134949
abnormal humoral immune response J:45665
abnormal immune tolerance J:45665
abnormal immunoglobulin level J:45665
abnormal Langerhans cell physiology J:134949
abnormal macrophage chemotaxis J:136628
abnormal nitric oxide homeostasis J:122801
abnormal redox activity J:122801
abnormal response to injury J:136628
abnormal response to new environment J:54250
abnormal spleen morphology J:47459
abnormal spleen red pulp morphology J:47459
abnormal spleen white pulp morphology J:47459
abnormal type IV hypersensitivity reaction J:45665
abnormal urine homeostasis J:118730
albuminuria J:118730
decreased interferon-gamma secretion J:120556
decreased interleukin-10 secretion J:120556, J:134949
decreased length of allograft survival J:44346
decreased susceptibility to injury J:108148
decreased vertical activity J:54250
enlarged mesenteric lymph nodes J:50832
enlarged spleen J:47459
extramedullary hematopoiesis J:47459
glomerulonephritis J:118730
normal immune system phenotype J:114783
impaired skeletal muscle regeneration J:136628
increased circulating interleukin-6 level J:47459
increased fear-related response J:54250
increased granulocyte number J:47459
increased interleukin-4 secretion J:120556
increased interleukin-12 secretion J:134949
increased leukocyte cell number J:47459
increased monocyte cell number J:47459
increased NK T cell number J:122801
increased susceptibility to bacterial infection J:47459
increased susceptibility to bacterial infection induced morbidity/mortality J:47459
increased susceptibility to parasitic infection J:50832
increased susceptibility to parasitic infection induced morbidity/mortality J:50832
increased susceptibility to type IV hypersensitivity reaction J:118730
increased susceptibility to xenobiotic induced morbidity/mortality J:91927
pale spleen J:47459
skeletal muscle fibrosis J:136628
stomach inflammation J:120556
Ifngtm1Ts/Ifngtm1Ts
C.129S7(B6)-Ifngtm1Ts/J 		abnormal adaptive immunity J:115144
abnormal circulating cytokine level J:47459
abnormal cytokine secretion J:115144
abnormal cytotoxic T cell physiology J:115144
abnormal inflammatory response J:115144
abnormal macrophage physiology J:115144
abnormal maternal decidual layer morphology J:56503
abnormal NK cell physiology J:115144
abnormal response to new environment J:54250
abnormal spleen morphology J:115144
abnormal spleen red pulp morphology J:47459
abnormal spleen white pulp morphology J:47459
abnormal tumor pathology J:115144
abnormal uterine NK cell morphology J:56503
abnormal uterine NK cell physiology J:56503
decreased litter size J:56503
decreased susceptibility to parasitic infection J:50832
decreased tumor latency J:115144
decreased vertical activity J:54250
enlarged spleen J:47459
extramedullary hematopoiesis J:47459
increased circulating interleukin-6 level J:47459
increased fear-related response J:54250
increased granulocyte number J:47459
increased leukocyte cell number J:47459
increased monocyte cell number J:47459
increased susceptibility to bacterial infection J:47459
increased susceptibility to bacterial infection induced morbidity/mortality J:47459
increased uterine NK cell number J:56503
pale spleen J:47459
Ifngtm1Ts/Ifngtm1Ts
C.129S7-Ifngtm1Ts 		abnormal cytokine secretion J:110826
abnormal humoral immune response J:45665
abnormal immune tolerance J:45665
abnormal immunoglobulin level J:45665
abnormal response to infection J:110826
increased interleukin-5 secretion J:110826
increased lung adenocarcinoma incidence J:77491
increased susceptibility to bacterial infection induced morbidity/mortality J:83180
increased susceptibility to experimental autoimmune encephalomyelitis J:34161
increased susceptibility to parasitic infection J:110826
increased susceptibility to parasitic infection induced morbidity/mortality J:110826
increased tumor latency J:77491
normal neoplasm J:77491
Ifngtm1Ts/Ifngtm1Ts
involves: 129S7/SvEvBrd 		abnormal cytokine level J:112600
abnormal immunoglobulin level J:29170
abnormal response to infection J:29170, J:110721
corneal vascularization J:114973
decreased susceptibility to type IV hypersensitivity reaction J:29170
impaired natural killer cell mediated cytotoxicity J:73948
increased IgG1 level J:110721
increased interleukin-17 secretion J:132905
increased susceptibility to bacterial infection J:110856
increased susceptibility to bacterial infection induced morbidity/mortality J:110856
increased susceptibility to Herpesvirales infection J:29170
increased susceptibility to Herpesvirales infection induced morbidity/mortality J:29170
Ifngtm1Ts/Ifngtm1Ts
involves: 129S7/SvEvBrd * A/WySn * C57BL/10SnSg * Swiss 		decreased IgG2a level J:119207
decreased IgG level J:119207
decreased physiological sensitivity to xenobiotic J:119207
decreased susceptibility to autoimmune disorder J:119207
increased IgG1 level J:119207
Ifngtm1Ts/Ifngtm1Ts
involves: 129S7/SvEvBrd * BALB/c 		abnormal susceptibility to infection J:39478
decreased airway responsiveness J:114213
decreased IgE level J:114213
decreased inflammatory response J:114213
normal immune system phenotype J:39881
increased airway responsiveness J:114213
Ifngtm1Ts/Ifngtm1Ts
involves: 129S7/SvEvBrd * C57BL/6 		abnormal macrophage physiology J:66802
abnormal MHC II cell surface expression on macrophages J:66802
abnormal NK cell physiology J:66802, J:115033
abnormal skin physiology J:55740
abnormal type IV hypersensitivity reaction J:55740
alveolar process atrophy J:147935
decreased length of allograft survival J:44346
decreased susceptibility to parasitic infection J:189794
decreased susceptibility to parasitic infection induced morbidity/mortality J:189794
decreased tumor incidence J:138466
normal immune system phenotype J:119206
increased metastatic potential J:152785
increased splenocyte proliferation J:66802
increased susceptibility to bacterial infection J:66802
Ifngtm1Ts/Ifngtm1Ts
involves: 129S7/SvEvBrd * C57BL/6J 		increased susceptibility to bacterial infection J:15723
increased susceptibility to bacterial infection induced morbidity/mortality J:15723
Ifngtm1Ts/Ifngtm1Ts
involves: 129S7/SvEvBrd * DBA/1 * MRL/Mp 		decreased anti-double stranded DNA antibody level J:39600
decreased anti-nuclear antigen antibody level J:39600
decreased autoantibody level J:39600
decreased IgA level J:39600
decreased IgG2a level J:39600
decreased IgG2b level J:39600
decreased IgG3 level J:39600
decreased IgM level J:39600
decreased immunoglobulin level J:39600
decreased susceptibility to autoimmune disorder J:39600
Ifngtm1Ts/Ifngtm1Ts
involves: 129S7/SvEvBrd * NOD 		normal immune system phenotype J:33427
Ifngtm1Ts/Ifngtm1Ts
NOD.129S7(B6)-Ifngtm1Ts/DvsJ 		abnormal cytotoxic T cell physiology J:72818
abnormal diapedesis J:72818
abnormal pancreatic beta cell physiology J:72818
decreased susceptibility to autoimmune diabetes J:72818
Ifngtm1Ts/Ifngtm1Ts
NOD.129S7-Ifngtm1Ts 		abnormal susceptibility to autoimmune disorder J:33427
decreased susceptibility to autoimmune diabetes J:95105
Ifngtm1Ts/Ifngtm1Ts
NOD.Cg-Ifngtm1Ts Prkdcscid 		decreased susceptibility to autoimmune diabetes J:72818
Ifngtm1Yiw/Ifngtm1Yiw
B6.129X1-Ifngtm1Yiw 		abnormal abdominal wall morphology J:50405
abnormal behavior J:50405
abnormal circulating interferon level J:91691
abnormal liver morphology J:50405
abnormal thoracic cavity morphology J:50405
ascites J:50405
focal hepatic necrosis J:91691
increased susceptibility to Coronaviridae infection J:50405, J:91691
increased susceptibility to Coronaviridae infection induced morbidity/mortality J:50405, J:91691
liver inflammation J:50405
peritoneal inflammation J:50405
Ifngtm1Yiw/Ifngtm1Yiw
C.129X1-Ifngtm1Yiw 		abnormal circulating interferon level J:91691
diffuse hepatic necrosis J:91691
increased circulating alanine transaminase level J:91691
increased susceptibility to Coronaviridae infection J:91691
increased susceptibility to Coronaviridae infection induced morbidity/mortality J:91691
Ifngtm1Yiw/Ifngtm1Yiw
involves: 129X1/SvJ * C57BL/6 		abnormal female reproductive system physiology J:59892
decreased apoptosis J:41632
decreased inflammatory response J:41632, J:88226
hepatic necrosis J:41632
Ifngtm3.1Lky/Ifngtm3.1Lky
B6.129S4-Ifngtm3.1Lky 		no abnormal phenotype detected J:183078
Ifngtm3.1Lky/Ifngtm3.1Lky
C.129S4-Ifngtm3.1Lky 		no abnormal phenotype detected J:183078
Tg(APCS-Ifng)5Imeg/0
involves: C57BL/6 * DBA/2 		abnormal circulating enzyme level J:16979
abnormal cytokine level J:135124
abnormal heart echocardiography feature J:135124
abnormal heart morphology J:135124
abnormal liver morphology J:16979
abnormal myocardial fiber morphology J:135124
cardiac interstitial fibrosis J:135124
cardiac muscle atrophy J:135124
cardiac muscle degeneration J:135124
chronic liver inflammation J:135124
decreased cardiac muscle contractility J:135124
dilated cardiomyopathy J:135124
dilated heart left ventricle J:135124
increased circulating alanine transaminase level J:135124
increased circulating interleukin-12 level J:135124
liver fibrosis J:16979
liver inflammation J:16979
liver vascular congestion J:135124
myocarditis J:135124
pancreas inflammation J:135124
premature death J:16979
Tg(GFAP-tTA)67Pop/0
Tg(tetO-Ifng)184Pop/0
B6.Cg-Tg(GFAP-tTA)67Pop Tg(tetO-Ifng)184Pop 		abnormal cerebellum external granule cell layer morphology J:94092
abnormal cerebellum morphology J:94092
ataxia J:94092
increased medulloblastoma incidence J:94092
normal mortality/aging J:94092
neonatal lethality, incomplete penetrance J:94092
postnatal growth retardation J:94092
postnatal lethality, complete penetrance J:94092
tremors J:94092
Tg(GFAP-tTA)67Pop/0
Tg(tetO-Ifng)184Pop/0
involves: 129S/SvEv * C57BL/6 * DBA/2 		increased medulloblastoma incidence J:94092
Tg(GFAP-tTA)78Pop/0
Tg(tetO-Ifng)184Pop/0
B6.Cg-Tg(GFAP-tTA)78Pop Tg(tetO-Ifng)184Pop 		abnormal cerebellum development J:109838
abnormal cerebellum external granule cell layer morphology J:109838
abnormal interferon-gamma secretion J:109838
ataxia J:109838
CNS inflammation J:109838
decreased body size J:109838
enlarged cerebellum J:109838
Tg(GFAP-tTA)110Pop/0
Tg(tetO-Ifng)184Pop/0
involves: 129S6/SvEvTac * C57BL/6 * DBA/2 * Swiss Webster 		ataxia J:99655
normal mortality/aging J:99655
tremors J:99655
Tg(Scgb1a1-rtTA,tetO-Ifng)14Eli/0
involves: C57BL/6 * CBA 		abnormal lung volume J:100854
emphysema J:100854
increased apoptosis J:100854
increased lung compliance J:100854
increased lymphocyte cell number J:100854
increased macrophage cell number J:100854
increased neutrophil cell number J:100854
Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
04/16/2024
MGI 6.23 		The Jackson Laboratory